[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-377994-105":59,"doc-detail-377994-en":135},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":128,"head_meta":130,"extra_data":132,"updated_unix":134},105,"en","complete-response-in-the-axilla-and-the-non-triple-negative-subtype-are-favourable-prognostic-factors-for-survival-outcomes-in-inflammatory-breast-cancer","Complete response in the axilla and the non-triple-negative subtype are favourable prognostic factors for survival outcomes in inflammatory breast cancer","","Aim: assess real-world outcomes and prognostic factors of non-metastatic inflammatory breast cancer by immunohistochemistry (IHC)-based subtype and treatment regimen. Methods: institutional retrospective analysis of stage III patients receiving neoadjuvant systemic treatment (NAST) between 2001 and 2018, evaluating survival by patient and tumor characteristics, treatment modality, and response to NAST. Results: 225 patients; 90% node-positive. Axillary pCR and non-triple-negative IHC subtype associated with improved RFS and OS; pCR and OS improved over time.",{"@graph":69,"@context":127},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/complete-response-in-the-axilla-and-the-non-triple-negative-subtype-are-favourable-prognostic-factors-for-survival-outcomes-in-inflammatory-breast-cancer/377994/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/complete-response-in-the-axilla-and-the-non-triple-negative-subtype-are-favourable-prognostic-factors-for-survival-outcomes-in-inflammatory-breast-cancer/377994.png","ImageObject",300,407,{"name":92,"@type":93},"\tCallum ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119,123],{"name":110,"@type":111,"acceptedAnswer":112},"What is the study aim regarding inflammatory breast cancer outcomes?","Question",{"text":113,"@type":114},"The study aims to evaluate real-world survival outcomes and prognostic factors in non-metastatic inflammatory breast cancer, stratified by IHC-based subtype and treatment regimen.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were patients treated before surgery in this analysis?",{"text":118,"@type":114},"All included patients received neoadjuvant systemic treatment (NAST), followed by locoregional treatment such as surgery and radiotherapy when appropriate, with adjuvant systemic therapy in selected patients.",{"name":120,"@type":111,"acceptedAnswer":121},"Which factors were identified as favourable prognostic indicators?",{"text":122,"@type":114},"Axillary pathologic complete response (pCR) and the non-triple-negative IHC-based subtype were favourable prognostic factors for relapse-free survival (RFS) and overall survival (OS).",{"name":124,"@type":111,"acceptedAnswer":125},"Did outcomes improve between earlier and later treatment periods?",{"text":126,"@type":114},"Yes. pCR rates and median OS improved over time, with higher values reported for the 2010–2018 period compared with 2001–2009.","https://schema.org",{"og:url":83,"og:type":129,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":131,"canonical":83},"index,follow",{"doc_id":133,"site_id":62},377994,1790792965,{"code":4,"msg":5,"data":136},{"doc_id":133,"user_id":137,"nickname":92,"user_avatar":138,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149},137451211410,"https://ap-avatar.wpscdn.com/avatar/2000bb0a9246f588df?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786362646172706240","The Breast 69 (2023) 481–490  \nContents lists available at ScienceDirect  \nThe Breast  \njournal [homepage:](homepage: www.journals.elsevier.com/the-breast)[ www.journals.elsevier.com/the-breast](homepage: www.journals.elsevier.com/the-breast)  \n| Complete response in the axilla and the non-triple negative subtype are favourable prognostic factors for survival outcomes in inflammatory breast cancer |  |  | |\n| --- | --- | --- | --- |\n| Cvetka Graˇsiˇc Kuhara, b, Simona Borˇstnara, b, Barbara Gazi´cb, c, Erika Matos a, b, *\u003Cbr>a Institute of Oncology Ljubljana, Department of Medical Oncology, Zaloˇska 2, 1000, Ljubljana, Slovenia b Faculty of Medicine Ljubljana, Vrazov Trg 2, 1000, Ljubljana, Slovenia\u003Cbr>c Institute of Oncology Ljubljana, Department of Pathology, Zaloˇska 2, 1000, Ljubljana, Slovenia |  |  |  |\n| A R T I C L E I N F O |  | A B S T R A C T |  |\n| Keywords:\u003Cbr>Inflammatory breast cancer Immunohistochemistry-based subtype Pathologic complete response Prognostic factors |  | Aim: To assess real-world outcomes and prognostic factors of non-metastatic inflammatory breast cancer according to immunohistochemistry (IHC)-based subtype and treatment regimen.\u003Cbr>Methods: An institutional retrospective analysis of patients treated with neoadjuvant systemic treatment (NAST) for stage III inflammatory breast cancer diagnosed between 2001 and 2018 was performed. The survival outcomes in relation to patient characteristics, tumour characteristics, treatment modality and response to NAST were analyzed.\u003Cbr>Results: 225 patients fulfilled the inclusion criteria, 90% of patients were node-positive. IHC-based subtypes: 39. 1% were HR+/HER2-, 19. 1% HR+/HER2+, 23. 1% HR-/HER2+ and 18.7% HR-/HER2-. Treatment was multimodal: NAST (100%), surgery (94.2%) and radiotherapy (94.2%). 53.3% of patients received adjuvant endocrine therapy, 34.3%(neo)adjuvant trastuzumab. Tri-modality therapy was applied in 89.3% of patients. Following NAST, a pathologic complete remission (pCR) in the breast was found in 16.9%, in the axilla in 29.7% and in both the breast and axilla in 10.3% of patients. The axillary pCR rate was significantly higher in HRsubtypes. Median overall survival (OS) was 8.9, 7.2, 5.8 and 2.3 years (p \u003C 0.001) for HR+/HER2-, HR+/ HER2+, HR-/HER2+ and HR-/HER2- subtype, respectively. On multivariate analysis, IHC-based subtype, age and axillary pCR were found as independent prognostic factors for RFS and OS. pCR rate and median OS improved over time, 5.8% vs 14.7% and 4.7 vs 10.0 years (2001–2009 vs. 2010–2018), respectively. Conclusions: Axillary pCR and the non-triple-negative IHC-based subtype are favourable prognostic factors for RFS and OS in inflammatory breast cancer. Introduction of taxanes and antiHER2 drugs contributed to improved pCR rate and OS. |  |\n\n1. Introduction  \nInflammatory breast cancer is a highly aggressive variant of breast cancer [1] and represents 1–2.5% of all breast cancers [2,3]. Although risk factors specific to inflammatory breast cancer are poorly defined, there is evidence of higher incidence in African American ethnicity, women with higher body mass index and younger age. Sparse epidemiological data suggest an association between pregnancy, lactation and inflammatory breast cancer [4]. Diagnosis of inflammatory breast cancer is based on clinicopathological criteria [5,6]. It is defined by the rapid appearance and progression of an erythema over at least one third of the breast, diffuse oedema and/or peau d’orange, and histological  \nconfirmation of invasive cancer. A history of this condition should be less than 6 months [6,7]. According to the 8th edition of the American Joint Committee on Cancer, inflammatory breast cancer is categorized as clinical stage T4d [7]. A typical but not specific pathologic feature is the presence of dermal lymphatic invasion, which could be confirmed by skin biopsy. The most common histology in inflammatory breast cancer is invasive carcinoma of no special type (NST) of","cbCaiqKo9qnSk1C6","https://ap.wps.com/l/cbCaiqKo9qnSk1C6","pdf",2907265,"English","# Introduction\n## Patients and diagnosis background\n# Methods and analysis\n## Study design and treatment\n## Outcomes assessed\n# Results\n## Patient characteristics and treatment patterns\n## pCR rates after NAST\n## Survival outcomes and prognostic factors\n## Trends over time\n# Conclusions","[{\"question\":\"What is the study aim regarding inflammatory breast cancer outcomes?\",\"answer\":\"The study aims to evaluate real-world survival outcomes and prognostic factors in non-metastatic inflammatory breast cancer, stratified by IHC-based subtype and treatment regimen.\"},{\"question\":\"How were patients treated before surgery in this analysis?\",\"answer\":\"All included patients received neoadjuvant systemic treatment (NAST), followed by locoregional treatment such as surgery and radiotherapy when appropriate, with adjuvant systemic therapy in selected patients.\"},{\"question\":\"Which factors were identified as favourable prognostic indicators?\",\"answer\":\"Axillary pathologic complete response (pCR) and the non-triple-negative IHC-based subtype were favourable prognostic factors for relapse-free survival (RFS) and overall survival (OS).\"},{\"question\":\"Did outcomes improve between earlier and later treatment periods?\",\"answer\":\"Yes. pCR rates and median OS improved over time, with higher values reported for the 2010–2018 period compared with 2001–2009.\"}]","Complete response in the axilla and the non-triple-negative subtype are favourable prognostic factors for survival outcomes in inflammatory breast cancer | PDF",1790227940,25]